Skip to main content

Prometheus Biosciences, Inc.

RXDXDelisted Jun 16, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001718852

Prometheus Biosciences, Inc. was delisted on Jun 16, 2023; its insiders filed their last Form 4 on Jun 16, 2023; 220 institutions reported holding it in 13F filings for Q1 2023, worth $4.35B in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
220
Q1 2023, +2 vs. previous quarter
13F value
$4.35B
Reported value at the end of Q1 2023
Superinvestors holding
0
At the end of Q1 2023

From SEC filings, in USD.

Revenue, FY2022
$6.81M
+117.6% year over year
Net income, FY2022
-$141.8M
No comparable prior period
Free cash flow, FY2022
-$126.0M
No comparable prior period
Revenue, Q1 FY2023
$1.10M
−71.8% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $141.8M (2081.8% of revenue).

Superinvestors holding RXDX, Q1 2023

Go to the superinvestors tab

No superinvestor reported holding RXDX at the end of Q1 2023.

Latest insider trades

See all insider trades

Open-market purchases and sales by Prometheus Biosciences, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 7, 2023 (view filing)Apr 52 daysMarshall Keith WChief Financial OfficerSSale−10.0K$108.42−$1.08M−50.5%9.81K after
Mar 17, 2023 (view filing)Mar 152 daysMcKenna Mark C.Chairman, President & CEOSSale−25.0K$116.14−$2.90M−31.2%55.1K after
Mar 8, 2023 (view filing)Mar 62 daysMarshall Keith WChief Financial OfficerSSale−10.0K$122.13−$1.22M−50.5%9.81K after
Mar 8, 2023 (view filing)Mar 8Same dayCedars Sinai Intellectual Property Co10% OwnerSSale−865.0K$114.59−$99.1M−17.8%4.00M after
Mar 3, 2023 (view filing)Mar 1-32 daysMcKenna Mark C.Chairman, President & CEOSSale−11.3K$125.14−$1.42M−17.0%55.1K after2 lots
Feb 17, 2023 (view filing)Feb 152 daysMarshall Keith WChief Financial OfficerSSale−5.00K$119.38−$596.9K−33.8%9.81K after
Feb 17, 2023 (view filing)Feb 15-172 daysMcKenna Mark C.Chairman, President & CEOSSale−63.7K$120.82−$7.69M−53.6%55.1K after3 lots
Jan 19, 2023 (view filing)Jan 172 daysMarshall Keith WChief Financial OfficerSSale−5.00K$119.00−$595.0K−33.8%9.81K after
Jan 19, 2023 (view filing)Jan 172 daysMcKenna Mark C.Chairman, President & CEOSSale−25.0K$118.99−$2.97M−31.2%55.1K after

Top 10 13F holders, Q1 2023

See all 220 holders

The largest institutional positions in Prometheus Biosciences, Inc. at the end of Q1 2023; share changes are against Q4 2022.

Institutions holding RXDX in Q1 2023
InstitutionSharesValue% of portfolioChange in sharesAction
RTW Investments, LP3,272,104$351.2M7.31%−82,199−2.5%Reduced
BlackRock Inc.2,799,818$300.5M0.01%−7,886−0.3%Reduced
Vanguard Group Inc2,716,901$291.6M0.01%+860,646+46.4%Added
Boxer Capital, LLC1,897,500$203.6M10.00%00.0%Unchanged
72 Investment Holdings, LLC1,848,024$198.3M93.93%00.0%Unchanged
Cormorant Asset Management, LP1,655,000$177.6M11.70%−435,000−20.8%Reduced
Point72 Asset Management, L.P.1,465,420$157.3M0.56%+199,337+15.7%Added
Fred Alger Management, LLC1,331,759$142.9M0.76%−27,497−2.0%Reduced
Perceptive Advisors LLC1,272,694$136.6M4.04%+60,000+4.9%Added
State Street Corp1,243,571$133.5M0.01%−104,609−7.8%Reduced